Q3 2025 BUSINESS UPDATE November 6, 2025 COPYRIGHT © ABCELLERA DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, includi ...

Financial Performance - Q1 2026 revenue reached $292.5 million, a 14% year-over-year increase[5] - Core IoT revenue experienced substantial growth, increasing by 74% year-over-year[5,6] - Non-GAAP EPS grew by 35% year-over-year, reaching $1.09[5,18] - Non-GAAP gross margin was 53.2%[6,16] - Cash flow from operations amounted to $30 million[16] Revenue Breakdown - Q1 2026 revenue distribution: Mobile contributed $41 million, Core IoT $104 million, and Enterprise & Auto $148 million[15] - Core IoT revenue accounted for 35% of the total revenue in Q1 2026[23] Q2 2026 Guidance (Non-GAAP) - Revenue is projected to be $300 million, with a variance of ± $10 million[31] - Gross margin is expected to be 53.5%, with a variance of ± 1.0%[31] - Operating expenses are estimated at $106 million, with a variance of ± $2 million[31] - EPS is forecasted to be $1.15, with a variance of ± $0.15[31] - Revenue mix forecast: Core IoT 31%, Enterprise & Auto 53%, and Mobile 16%[31]

November 2025 1 P L E A S E R E F E R T O S L I D E 2 F O R T H E S A F E H A R B O R L A N G U A G E R E G A R D I N G T H I S P R E S E N T A T I O N 3 rd Quarter 2025 Earnings Supplement Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 193 ...

Financial Performance - Q3 2025 revenue reached approximately $592 million, a year-over-year increase of about 35% compared to approximately $440 million in Q3 2024[8] - Approximately 894,000 total tests were processed in Q3 2025, reflecting a year-over-year growth of about 15% from approximately 776,000 in Q3 2024[8] - Clinical MRD tests numbered approximately 202,000 in Q3 2025, a year-over-year increase of about 56% from approximately 130,000 in Q3 2024[8] - Gross margin was approximately 65% in Q3 2025, with approximately $26 million in cash inflow generated[8] - The 2025 financial outlook was increased by $160 million, projecting revenue between $218 billion and $226 billion, gross margin between 62% and 64%, and $100 million in cash flow generation[8] Product Development and Data - A newly expanded 20-gene panel for Fetal Focus is launching in Q4[29] - Early cancer detection data for advanced adenomas was announced[8] - Strong Signatera data was presented at ESMO, reinforcing MRD leadership[8] Clinical Data and Studies - ESMO Congress presented practice-changing evidence in muscle-invasive bladder cancer[33] - Strong Signatera data in colorectal cancer was presented at ESMO, with a publication in Nature[36] - Overall advanced adenoma performance showed 225% sensitivity (CI: 154%-324%) and 915% specificity (CI: 882%-939%)[44]

Key Operating Metrics - Global studios increased by 8% year-over-year, reaching 3,066[13] - Global licenses increased by 3% year-over-year, totaling 5,318[13] - System-wide sales in North America increased by 10% year-over-year, reaching $432 million[14] - Run-Rate AUV in North America increased by 2% year-over-year, reaching $668,000[14] - Same-store sales increased by 7% year-over-year for studios open greater than 36 months[21] - Total members decreased by 1% to 796,000[21] Financial Performance - Revenue decreased by 2% year-over-year to $79 million[25] - Adjusted EBITDA increased by 9% year-over-year to $33 million, with a margin of 42% compared to 38% in the previous year[25, 33] - Adjusted net earnings per share - diluted is $034, compared to ($005) in Q3 2024[30] Future Outlook (FY 2025 Guidance) - The company anticipates between 170 and 190 net new studio openings globally, a -37% change vs 2024[35] - System-wide sales in North America are projected to be between $173 billion and $175 billion, a 12% increase compared to 2024[35] - Revenue is expected to be between $300 million and $310 million, a -5% change vs 2024[35] - Adjusted EBITDA is projected to be between $106 million and $111 million, a -7% change vs 2024[35]

Third Quarter 2025 © 2025 RB Global, Inc. | All Rights Reserved Forward-Looking Statements Forward-Looking Statements: Certain statements contained in this presentation include "forward-looking statements" within the meaning of U.S. federal securities laws and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements herein include, in particular statements relating to future financial and operational results, opport ...

Earnings Q3 2025 November 2025 Disclaimer This presentation is made by OneStream, Inc. (the "Company," "we," "our" or "we") and contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation may be forward -looki ng statements. In some cases, you can identify forward - looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," ...

Puma Biotechnology Earnings Call Commercial Update Puma's Pharmacy and Distributor Network Copyright 2025 Puma Biotechnology 3 November 6, 2025 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated res ...

Q3 2025 Performance Highlights - Total revenue reached $286 million[8] - Adjusted EBITDA margin was 25%[8, 12] - Free cash flow margin was 13%[8, 12] - Dollar Based Retention Rate (DBRR) was 107%[8, 12] AI Metrics in Q3 2025 - Enterprise AI revenue experienced year-over-year growth of 41%[13] - AI contributed 11% to enterprise subscription revenue[13] - Enterprise AI bookings grew by over 80% year-over-year[13] - AI accounted for over 20% of enterprise new logo ACV bookings[13] - AI was virtually always attached to $1M+ ARR new logo deals[13] Financial Guidance and Share Repurchase Program - The company authorized a $150 million share repurchase program expiring on December 31, 2027[9, 11] - An Accelerated Share Repurchase (ASR) agreement is intended to repurchase $50 million of common stock, with final settlement expected by the end of Q1 2026[11] - Q4 2025 revenue is projected to be between $2947 million and $300.7 million[36] - Full-year 2025 revenue is guided to be between $1.1435 billion and $1.1495 billion[36]

Q3 2025 Performance - Consumables revenue reached $285 million in Q3 2025, representing an 8% year-over-year growth[8] - Systems revenue increased to $174 million in Q3 2025, a 9% year-over-year increase[8] - Vital Care revenue declined significantly to $74 million in Q3 2025, a 52% year-over-year decrease[8] - Total ICU Medical revenue was $533 million in Q3 2025, reflecting an 8% year-over-year decrease[8] 2025 Guidance Update (Post JV Transaction) - Adjusted EBITDA is projected to be between $395 million and $405 million[9] - Adjusted EPS is expected to be between $735 and $765[9] - Consolidated revenue is expected to have a ~ (6%) FXN impact, with low to mid single digits organic growth[9] - Vital Care is expected to have a ~ (35%) FXN impact, with flat organic growth[9] - Net interest expenses are projected to be around $19 million in Q4[9] - Capital expenditures are estimated to be between $85 million and $95 million[9]